What question did this study set out to answer?

Assess the impact of biosimilar entry on the prices of originator biologics covered under Medicare Part B.

November 11, 2025JAMA Network OpenOpen Access

Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market

View Full Paper

Ask AI

Bookmark

Authors

AAAbdelaziz Abdullah WNWinn, Aaron N.DBDusetzina, Stacie B

Discussion

Member takes

Implication

Cohort study shows that biosimilars significantly reduce originator biologic prices in Medicare Part B, indicating need for market competition reforms.

Key Points

Assess the impact of biosimilar entry on the prices of originator biologics covered under Medicare Part B.
Cohort study
Analyzed Medicare Part B Drug average sales price data from 2005 to 2025
Utilized bayesian structural time series models to estimate price differences
Biosimilar entry associated with 43.1% reduction in originator prices over 5 years
Savings varied by drug, with pegfilgrastim showing 82% price reduction
Biosimilar prices consistently lower than originator prices post-entry

Cite This Study

Abdullah et al. (2025) studied this question.

synapsesocial.com/papers/69252ea3c0ce034ddc3566b2 https://doi.org/10.1001/jamanetworkopen.2025.42937

View Full Paper

Ask AI

Bookmark

Implication

Cohort study shows that biosimilars significantly reduce originator biologic prices in Medicare Part B, indicating need for market competition reforms.

Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market

Discussion

Member takes

Implication

Key Points

Cite This Study

Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider